3-(吡啶-2-基)-5-[3-(三氟甲氧基)苯基]-1,2,4-噁二唑 | 327056-14-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(吡啶-2-基)-5-[3-(三氟甲氧基)苯基]-1,2,4-噁二唑
• 英文名称: 3-(pyridin-2-yl)-5-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole
• 英文别名: 3-(2-pyridyl)-5-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole；3-pyridin-2-yl-5-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole
• CAS: 327056-14-4
• 化学式: C₁₄H₈F₃N₃O₂
• 分子量: 307.232
• InChiKey: DKASLOPISBVXCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-(三氟甲氧基)苯甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 3-(吡啶-2-基)-5-[3-(三氟甲氧基)苯基]-1,2,4-噁二唑
  参考文献：
  名称：

  Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development

  摘要：

  AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.100

文献信息

• Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：——

  公开号：US20030055085A1

  公开（公告）日：2003-03-20

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  本发明提供了作为代谢型谷氨酸受体拮抗剂的化合物和药物组合物，用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。
• HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1210344A1

  公开（公告）日：2002-06-05
• NEW USE
  申请人：AstraZeneca AB

  公开号：EP1896011A1

  公开（公告）日：2008-03-12
• METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE
  申请人：Pharmalundensis AB

  公开号：EP2672971A1

  公开（公告）日：2013-12-18
• New use
  申请人：Lehmann Anders

  公开号：US20070010553A1

  公开（公告）日：2007-01-11

  The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment or prevention of cough.